Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Norelgestromin,Ethinyl Estradiol

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Evra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gedeon Richter Plc.

            Deal Size: $263.5 million Upfront Cash: Undisclosed

            Deal Type: Acquisition December 03, 2020

            Details:

            Evra is a transdermal contraceptive patch assets. The deal is complemented by a transitional business license agreement and series of other related agreements to run the business without interruption during the period required to transfer marketing authorizations to Richter.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Estradiol

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Imvexxy

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cantor Fitzgerald

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering November 10, 2020

            Details:

            TherapeuticsMD intends to use the net proceeds from the offering for commercialization of its three FDA-approved products which includes IMVEXXY®, BIJUVA® and ANNOVERA®, and for working capital and general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Norethindrone Acetate,Ethinyl Estradiol,Ferrous Fumarate

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Gemmily

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            Taytulla® is an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy. Annual market sales for Taytulla® for the twelve month period ending August, 2020 were $157 million, according to IQVIA™.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Phexxi

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 08, 2020

            Details:

            Approved by the U.S. Food and Drug Administration (FDA) on May 22, 2020, Phexxi is a vaginal pH modulator designed to maintain vaginal pH within the normal range of 3.5 to 4.5 – an acidic environment that is inhospitable to sperm.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bremelanotide

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: AMAG Pharmaceuticals

            Deal Size: $16.3 million Upfront Cash: $12.0 million

            Deal Type: Divestment July 27, 2020

            Details:

            Under the terms of the termination agreement, all of AMAG’s rights and obligations to develop and commercialize Vyleesi under the license agreement will terminate, and full ownership of Vyleesi will transfer back to Palatin.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Annovera

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: TherapeuticMD

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 15, 2020

            Details:

            The agreement is aimed at expanding access to ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), a first of its kind annual birth control ring. ANNOVERA is the first FDA-approved long-lasting birth control method that does not require a medical procedure.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Phexxi

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 15, 2020

            Details:

            The final data analysis demonstrated a cumulative pregnancy rate of 13.7% over seven cycles of use in Phexxi group.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 22, 2020

            Details:

            Data demonstrate high efficacy rates of more than 93% when Phexxi is used as directed, also underscore the sexual satisfaction and lubricating factors experienced by women in the AMPOWER trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: TherapeuticsMD

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 13, 2020

            Details:

            The arrangement combines Afaxys' unique capabilities serving the United States public health contraception market with TherapeuticsMD’s commitment to supply ANNOVERA to the U.S public health system.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Etonogestrel

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Nexplanon

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: NewCo

            Deal Size: $9.0 million Upfront Cash: Undisclosed

            Deal Type: Divestment February 05, 2020

            Details:

            Merck will retain its current growth pillars of Oncology, Vaccines, Hospital and Animal Health and continue to invest in research and development of breakthrough innovations across all areas of science.

            PharmaCompass